GlassScriptPhysician profile
Firas El-Baba
NPI 1568997062
$622.13
in general payments reported to CMS, 2019-2025
13 companies · $151 in 2025
The $151 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $59.11 · 2021: $39.76 · 2022: $75.00 · 2024: $297 · 2025: $151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $448.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $448.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $98.87 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $97.73 | 2022-2024 | Winrevair |
| Amgen INC. | $72.19 | 2024 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $55.62 | 2024-2025 | Dupixent |
| Genzyme Corporation | $55.21 | 2024-2025 | |
| United Therapeutics Corporation | $45.18 | 2024-2025 | Tyvaso, Tyvaso |
| Actelion Pharmaceuticals US, INC. | $40.02 | 2024 | Opsumit, Uptravi |
| Astrazeneca Pharmaceuticals LP | $33.58 | 2024 | Fasenra |
| Axsome Therapeutics, INC. | $30.28 | 2025 | Sunosi |
| Harmony Biosciences LLC | $26.88 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $26.21 | 2024 | |
| Baxter Healthcare | $25.15 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Glaxosmithkline, LLC. | $15.21 | 2025 | Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Firas El-Baba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.